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Despite major advances in the treatment of hematologi-
cal diseases over the last decades, allogeneic hematopoi-
etic stem cell transplantation (alloHSCT) still remains the 
only curative option for many of them. According to the 
recent survey of the European Society of Blood and Mar-
row Transplantation (EBMT), nearly 15 000 alloHSCT are 
currently performed each year across Europe and EBMT-
affiliated countries (1).
Approximately 50% of these patients will develop a major 
late complication – chronic graft-vs-host disease (cGVHD), 
a multi-organ allo- and auto-immune disorder affecting 
the skin, lungs, mouth, liver, eyes, joints, and gastrointes-
tinal and genital tracts (2-4). As a multisystem disease in 
these long-term survivors after alloHSCT, it presents with 
a number of heterogeneous clinical manifestations requir-
ing a multidisciplinary approach both in its diagnosis and 
treatment.
Chronic GVHD can last for many years causing severe 
medical, social, and quality of life problems, as well as sig-
nificantly impacting health-related costs and health care 
management. A recently published report from the Cen-
ter for International Blood and Marrow Transplant Research 
has identified a clear increase in the incidence of cGVHD 
from 1995 to 2007 due to the more frequent use of periph-
eral blood graft instead of bone marrow, unrelated donors, 
and older recipients (5). In addition, because of increasing 
safety of alloHSCT and better supportive care, there are 
more long-time survivors after alloHSCT and hence more 
patients are at risk of developing cGVHD (5).
cGVHD has been much better characterized using inter-
nationally recognized diagnostic criteria and scoring mea-
surements since the first National Institutes of Health (NIH) 
Consensus classification was developed in 2005 and pro-
spectively validated (3,6-10). However, there are still plenty 
of issues in addressing challenges posed by cGVHD to cli-
nicians and academic researchers. In June 2014, the sec-
ond cGVHD consensus conference was held at the Na-
tional Cancer Institute (NCI), NIH, USA, attended by 250 
participants from all over the world. A number of updated 
evidence-based recommendations were proposed at this 
conference and are detailed in the six new consensus pa-
pers published during 2015 in the Biology of Blood and 
Marrow Transplantation journal (4,11-15). These new rec-
ommendations should further advance cGVHD clinical re-
search related to diagnosis, staging, histopathology evalu-
ation, biomarkers, response criteria, design of clinical trials, 
estimating prognosis, guiding therapeutic decisions, an-
cillary and supportive care, as well as standardizing docu-
mentation.
The German-Austrian-Swiss cGVHD consortium assessed 
the usefulness of the NIH criteria in routine clinical prac-
tice and reported high rates of acceptance for definitions 
of cGVHD, as well as overall and organ-specific NIH cGVHD 
severity scoring among the vast majority of participants 
(16). An international survey of the EBMT-NCI cGVHD Task 
Force conducted in 2013 confirmed substantial national 
and international support for use of the NIH Consen-
sus criteria in everyday clinical practice (17). With the 
goal to implement the newest diagnostic criteria 
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and clinical standards for cGVHD in Croatia, a multidisci-
plinary clinical infrastructure for cGVHD was established 
at the University Hospital Center Zagreb in the middle of 
2013, supported by the Unity Through Knowledge Fund 
project entitled “Clinical and Biological Factors Determin-
ing Severity and Activity of Chronic Graft-Versus-Host Dis-
ease after Allogeneic Hematopoietic Stem Cell Transplan-
tation” funded by the World Bank and Croatian Ministry of 
Science, Education and Sports. Until now, 53 cGVHD pa-
tients have been prospectively evaluated in Zagreb by a 
multidisciplinary team of subspecialists in hematology, 
dermatology, dentistry, ophthalmology, physical therapy, 
pulmology, gynecology, nutrition, neurology, and other 
specialties when needed, with a collection of standardized 
demographic, clinical, laboratory, histopathology, and im-
aging data. Moreover, additional 43 transplanted patients 
without cGVHD were evaluated by Zagreb’s team to serve 
as controls. This approach improved the consistency of as-
sessment and treatment of patients with cGVHD and also 
validated the care-models and standards put forward by 
the internationally developed NIH criteria. This initiative is 
also playing a pivotal role in promoting interdisciplinary 
and international collaboration, stimulating education, ex-
change, and networking of researchers and clinicians, as 
well as the development of several scientific subprojects 
on this often devastating chronic disease.
Therefore, there has been significant research activity and 
renewed interest in cGVHD in the world over the last de-
cade. It is likely that the current better characterization of 
cGVHD, standardization of research tools, and numerous 
new treatment opportunities will lead to improved clinical 
outcomes, such as clinical symptoms, function status, qual-
ity of life, morbidity, and survival.
However, not a single agent has yet been approved for 
cGVHD prevention or treatment, neither by the US Food 
and Drug Administration (FDA) nor by the European Medi-
cines Agency (EMA). The current standard front-line steroid 
therapy has a 50% failure rate with significant toxicity, and 
there are no standards for second-line (and beyond) thera-
peutic options.
The focus now in this field is on further in-depth study 
of the biology of cGVHD, developing and validating new 
biomarkers, and pursuing clinical trials of new agents that 
would eventually develop pathways to their FDA and EMA 
regulatory approvals. The aim is to develop more effec-
tive, less toxic, and more targeted treatments that will 
not interfere with the beneficial graft-vs-tumor ef-
fects. To advance this field and break the 30-year-old sub-
optimal treatment paradigms, the goal is that each cGVHD 
patient should be either treated in a clinical trial or at least 
should be documented within a registry capturing essen-
tial clinical data on the course of cGVHD. The tools and op-
portunities to harness cGVHD and create better and saf-
er alloHSCT are in our hands right now. This issue of the 
Croatian Medical Journal presents several excellent articles 
that are a product of these enhanced international col-
laborations and efforts by teams across Europe to address 
cGVHD.
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